Wellcome Trust

U.K. firm will steer portfolio toward returns for shareholders, while aiming to build new fund away from public markets

BMS acquires Karuna, brightening the spotlight on schizophrenia, muscarinic receptors and neurology

Financing policies include streamlined trial approvals, investment vehicles for pensions

Results validate CEO Steven Paul’s ‘simple but elegant’ approach to improving xanomeline’s tolerability in schizophrenia patients

Partnership kick-starts AMR innovation, but progress on U.S. pull incentives awaits Congressional action 

Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close

Early investors including Andera, OrbiMed gain liquidity in deal worth up to $525M, giving Pfizer an antiviral for RSV

The Coalition for Epidemic Preparedness Innovations is gearing up to take the fight beyond COVID-19

WHO backing mRNA vaccine capacity, Korea providing a global biomanufacturing training center

Merck executive brings deep experience with infectious disease, patient engagement and public health emergencies to the non-profit